OTC Pediatrics - US - March 2014
US $4,395.00 (Excl.Tax)Excl. Tax Buy Now
“After a series of product recalls, the OTC pediatrics market appears to have fully recovered. However, the market faces a few challenges to growth, including a declining population of households with children, and an overall movement toward prevention rather than treatment. Manufacturers and retailers that can meet parents’ unique needs will be best positioned to maximize sales.”
– Emily Krol, Health and Wellness Analyst
Some questions answered in this report include:
Illness is prevalent among children, as more than 85% of children younger than 12 experienced some type of ailment in the past year. Their lower immune system combined with opportunities for interaction and germ spreading makes them especially susceptible to illness.
Despite a string of product recalls from a few high-profile brands, the OTC (over-the-counter) pediatrics market has continued to grow, fueled by the return to market of most top-selling brands. When it comes to illness, parents will spend on products to help their children feel better as quickly as possible.
This report explores parents’ attitudes toward children’s OTC medications, including private label and name brand medications. The report will also discuss opportunities for product innovation. Usage of and attitudes toward children’s vitamins will also be presented.
This report builds on the analysis presented in Mintel’s OTC Pediatrics – US, August 2012, as well as the November 2010 and October 2008 report of the same title.
The OTC pediatrics products market, as defined by Mintel for this report, includes children’s strength versions of OTC medications and vitamins/minerals/supplements. This includes remedies that are designed to treat children younger than 12, including babies and toddlers.
The market is segmented as follows:
The report excludes lice treatments and health accessories (thermometers, bandages, braces, vaporizers, etc) as well as prescription medications.
The market size is based on specific brands of children’s medications. In some cases, available point-of-sale data do not differentiate between children’s and adult versions that share the same brand name. Mintel estimated sales of those brands, as well as private label versions of OTC pediatrics, based on similarities with identified brands and additional research on the market.
Value figures throughout this report are at rsp (retail selling prices) excluding sales tax unless otherwise stated.
This report will give you a complete 360-degree view of your market. Not only is it rooted in robust proprietary and high-quality third-party data, but our industry experts put that data into context and you’ll quickly understand:
What They Want. Why They Want It.
Who’s Winning. How To Stay Ahead.
Size, Segments, Shares And Forecasts: How It All Adds Up.
New Ideas. New Products. New Potential.
Where The White Space Is. How To Make It Yours.
What’s Shaping Demand – Today And Tomorrow.